Recent studies indicate that abnormal levels of low-density lipoprotein (LDL), which is an important component of dyslipidaemia, are associated with alterations to cancer risk, including that of renal cell carcinoma (RCC). Single nucleotide polymorphisms at microRNA-binding sites contribute to cancer susceptibility and progression by affecting the messenger RNA (mRNA) function of target genes. In this case-control study, we examined the frequency of six potentially functional single nucleotide polymorphisms in the LDL receptor gene (LDLR) in 1004 clear cell RCC (ccRCC) patients and 1065 cancerfree subjects. Logistic regression analyses estimated odds ratios (ORs) and 95% confidence intervals (CIs). The association between genetic variants and levels of LDLR mRNA and protein was also evaluated. Compared with the CC genotype, multivariate logistic regression analysis showed that the LDLR rs2738464 variant GG genotype was associated with a significantly decreased ccRCC risk (P = 0.002, OR: 0.605, 95% CI: 0.439-0.833). Further functional experiments showed that the rs2738464 variant G allele affected miR-330 regulation of the LDLR 3′-untranslated region (UTR), increasing LDLR mRNA levels in patient kidney tissues. These findings suggest that LDLR rs2738464 may affect the affinity of miR-330 binding to the LDLR 3′-UTR, thus regulating LDLR expression and contributing to ccRCC risk.
Introduction
Renal cell carcinoma (RCC) accounts for 2-3% of all adult malignancies, and its incidence has increased over recent decades (1) . Although the mechanisms responsible for RCC remain unknown, environmental factors and genetic background are thought to play a critical role in RCC carcinogenesis (2) . For example, accumulating evidence shows that altered lifestyle factors, and subsequent obesity and hypertension, may partially explain the aetiology of RCC (3, 4) .
Recent studies have proposed that RCC should be regarded as a metabolic disorder because each of the known RCC genes identified to date is involved in pathways that respond to metabolic stress and/or nutrient stimulation (5) . However, clear cell RCC (ccRCC), the main histological type of RCC, is commonly associated with genetic and epigenetic alterations in the von Hippel-Lindau tumour suppressor gene (6, 7) . Single nucleotide polymorphisms (SNPs) are another genetic aspect that can affect RCC risk (8, 9) .
Recently, interest has been focused on the role of dyslipidaemia, a predominant component of metabolic disorders, in the formation and progression of various cancers, including RCC. ccRCC is characterized by sterol storage in tumour cells, which suggests an abnormality in lipid metabolism. Fluvastatin, a synthetic statin used for the treatment of dyslipidaemia, was reported to notably inhibit tumour growth, invasion, angiogenesis and metastasis of RCC cells in vitro (10) . Moreover, in a prospective study, Ahn et al. observed a decreased risk of RCC associated with higher serum cholesterol levels, albeit with marginal statistical significance (11) . Another prospective cohort study reported that serum triglyceride levels were significantly associated with increased RCC risk (12) . Similarly, we previously observed a strong, independent, positive association between high low-density lipoprotein (LDL) levels and RCC risk in the Chinese population (13) . In light of the important role of dyslipidaemia in RCC development, we hypothesized that genetic variations in the lipid metabolism pathway, including the LDL receptor (LDLR), might contribute to RCC carcinogenesis.
Abundant evidence indicates that microRNAs (miRNAs), a type of small non-coding RNA, function as either oncogenes or tumour suppressors by specifically binding and cleaving target gene messenger RNA (mRNAs) or inhibiting their translation. These target genes participate in diverse cellular processes, such as cell differentiation, proliferation, apoptosis, angiogenesis and metastasis (14, 15) . Recent studies have demonstrated that SNPs at miRNA binding sites may regulate the biogenesis and/or function of the corresponding miRNAs, thereby influencing the development of several cancers (16, 17) . However, to date, no study has explored the association of LDLR polymorphisms with RCC risk, or their potential role in RCC carcinogenesis. We, therefore, conducted a case-control study in the Chinese Han population to investigate the relationship between potential functional variants located at the miRNA binding sites of LDLR, with ccRCC risk. We also examined the association between the genotype of identified functional SNPs and both mRNA and protein levels of LDLR, as well as allelic functionality.
Materials and methods

Subjects
This case-control study consisted of 1012 ccRCC patients from Fudan University Shanghai Cancer Center (FUSCC) recruited between January 2006 and December 2010. Among the patients who were pathologically confirmed at the FUSCC Department of Pathology and classified using the criteria of the American Joint Committee on Cancer TNM classification, 870 cases underwent surgical removal and 142 were diagnosed by percutaneous renal mass biopsy. None of them reported a history of chemotherapy or radiotherapy, and 95 cases received cytokine therapy before hospitalisation. All fasting peripheral blood samples from patients were obtained before surgery or biopsy and were preserved at −80°C. Data on age, sex, body mass index (BMI), smoking status, alcohol consumption, Fuhrman grade and TNM staging were acquired from electronic medical records. From the cases, we enrolled 188 consecutive patients in 2009 and 100 consecutive patients in 2010 for further LDLR mRNA and protein analysis. Controls were from the Taizhou Longitudinal (TZL) study (18) . The TZL study was initiated in 2007 and was a three-phase open-ended prospective study. All the controls in our study were from phase II, who received a face-to-face interview to complete a questionnaire including baseline demographic information and medical history, and donated fasting blood for biochemical measurement and DNA extraction. A total of 1163 cancer-free controls matched for age and sex with the cases were selected. All cases were from Eastern China, including Shanghai, Jiangsu Province, Zhejiang Province and surrounding areas; controls were recruited from the same region. The TZL study and the patient study were approved by the Human Ethics Committee of Fudan University and the Human Ethics Committee of FUSCC, respectively. The research protocol was approved by the Institutional Research Review Boards of FUSCC. The study was carried out in accordance with the ethical standards of Helsinki Declaration II, and all subjects provided written informed consent.
Identification and in silico analysis of functional variants
According to the dbSNP database of the National Center for Biotechnology Information (NCBI, https://www.ncbi.nlm.nih.gov/projects/SNP) and the International HapMap Project database (http://hapmap.ncbi.nlm.nih. gov/), we assessed SNPs located at the 3′-untranslated region (UTR) of LDLR based on the following criteria: (1) minor allele frequency ≥5% in the Chinese Han population; (2) low linkage disequilibrium with each other using a threshold of r 2 < 0.8; (3) predicted to be a potentially functional SNP according to the National Institute of Environmental Health Sciences (http://snpinfo.niehs.nih.gov/snpfunc/htm) and (4) having the potential to affect miRNA binding. As a result, six SNPs were selected for further genotyping. We also used miRBase (http://www.mirbase.org/) and TargetScan Human 6.2 (http://www.targetscan.org) to predict miRNA target genes, and the RNAfold online tool (http://rna.tbi.univie.ac.at/) to predict RNA secondary structure based on minimum free energy (MFE) values.
DNA extraction and genotyping
Total genomic DNA was obtained using proteinase K digestion and phenol-chloroform extraction, and genotyping was performed using the TaqMan assay as described previously (19) . For quality control, we included two negative controls (with no DNA sample) and two positive controls in each 384-well plate. Additionally, 5% of samples were selected randomly for repeated genotyping to assess reliability. For samples with inconsistent results, we repeated genotyping. Eight cases and 98 controls were excluded from further analyses because of unqualified DNA samples. The genotyping rate was 95.1%, with 100% concordance achieved for all results.
RNA and miRNA extraction, and quantitative real-time-PCR
Total RNA was extracted from adjacent normal kidney tissues using Trizol reagent (Life Technologies, Carlsbad, CA). First-strand complementary DNA (cDNA) was synthesized using the RevertAid™ First-Strand cDNA synthesis Kit (Life Technologies, Carlsbad, CA). mRNA levels were measured by quantitative real-time (qRT)-PCR using the Power SYBR Green PCR Master Mix (Life Technologies), with β-actin as an internal control. The primer sequences are listed in Supplementary Table S2, available at Carcinogenesis Online.
Total miRNA was extracted from cultured cells using the miRcute miRNA Extraction Kit (Tiangen Biotech, Beijing, China) and used to synthesize first-strand cDNA with the miRcute miRNA cDNA Synthesis Kit (Tiangen Biotech). qRT-PCR was performed using the miRcute miRNA SYBR Green Kit (Tiangen Biotech). miRNA primers were provided by Tiangen Biotech. 5S was used as an internal control. 
Abbreviations
Cloning and site-directed mutagenesis
A 192 bp fragment of the human LDLR 3′-UTR containing the rs2738464 C allele was amplified from a homozygous human genomic DNA sample by nested PCR (Supplementary Table S2 , available at Carcinogenesis Online). Using NotI and XhoI endonucleases, the purified PCR product was cloned into the psiCHECK TM -2 vector (Promega, Madison, WI) and named psiCHECK2:rs2738464C. The rs2738464 G allele was generated using the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) as directed by the manufacturer, and the plasmid was named psiCHECK2:rs2738464G. All plasmid DNA constructs were verified by direct sequencing (Supplementary Figure S1 , available at Carcinogenesis Online).
Cell culture, transient transfection and luciferase assays
Three human RCC cell lines (786-O, ACHN and Caki-1 cells), human cervical adenocarcinoma cells (HeLa), human embryonic kidney 293T cells (HEK293T) and human kidney proximal tubular cells (HK-2) were purchased from the Institute of Cell Research of the Chinese Academy of Sciences (Shanghai, China) and cultured at 37°C in 5% CO 2 . 786-O and HK-2 cells were grown in RPMI 1640 medium, ACHN and HeLa cells were cultured in MEM medium, and HEK293T and Caki-1 cells were cultured in DMEM medium and McCoy's 5A medium, respectively. All media (Gibco, Gaithersburg, MD) were supplemented with 10% foetal bovine serum (Hyclone, Logan, UT). All cells were used within 3 months after resuscitation. miRNA mimics were synthesized by Ribobio (Guangzhou, China). For transfection, cells were cultured in 6-well plates overnight and co-transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as directed by the manufacturer. The co-transfection reaction system included the miRNA mimic with psiCHECK2:control, psiCHECK2:rs2738464C or psiCHECK2:rs2738464G plasmid DNA. Fortyeight hours after transfection, cells were lysed using 50 µL passive lysis buffer. Then, a dual-luciferase assay was performed according to the manufacturer's protocol (Promega). The ratio of Renilla to firefly luciferase activity was used to denote luciferase activity. All experiments were carried out in triplicate.
Levels of LDLR protein in target tissue according to LDLR genotype
Immunohistochemical (IHC) staining of paraffin-embedded specimens from the constructed 10 × 12 tissue microarray (TMA) was performed as previously described to detect LDLR protein (20) . Briefly, TMAs were soaked with 3% H 2 O 2 -methanol for 15 min to block peroxidase activity after antigen retrieval and were then incubated with 10% normal goat serum to block non-specific protein binding. Next, TMAs were incubated with a primary antibody against LDLR (Abcam, Cambridge, UK) (1:100) and then with an anti-mouse/rabbit horseradish peroxidase-labelled antibody (Univ-bio, Shanghai, China) as a secondary antibody. LDLR staining was scored as negative, weakly positive, or strongly positive, by a professional pathologist who was blinded to patient information.
Statistical analysis
Hardy-Weinberg equilibrium for the controls, as well as SNP differences between cases and controls, was tested using Pearson's chi-squared tests. Differences between continuous variables, such as luciferase activity and LDLR mRNA levels, were calculated by Student's t-test, the Wilcoxon test or analysis of variance (ANOVA). Unconditional logistic regression models were used to estimate crude and adjusted odds ratio (ORs) for ccRCC risk and 95% confidence intervals (CIs), which were further stratified by age, sex, BMI, smoking status ('ever/current' or 'never'), tumour staging and Fuhrman grade. In logistic regression models, age and BMI were included as continuous variables, and sex and smoking states were included as categorical variables. False-positive report probability (FPRP) was calculated with prior probabilities of 0.0001, 0.001, 0.01, 0.1 and 0.25 to test for falsepositive associations for all significant genetic effects, and a probability of <0.2 was considered noteworthy (21) . Statistical significance was based on two-sided P-values of <0.05, and all analyses were performed with SAS software (Version 9.2; SAS Institute, Cary, NC). 
Results
Characteristics of the study subjects
Association of LDLR SNPs with ccRCC risk
Among the six selected SNPs, rs3826810 was excluded from further analysis because all subjects were shown to be homozygous wild-type (AA). The distributions of the control genotype were all in agreement with Hardy-Weinberg equilibrium (P > 0.05, Table 2 ). The genotype frequencies of the other five SNPs and their associations with ccRCC risk are shown in Table 2) .
In a stratified analysis, we observed that the decreased ccRCC risk associated with rs2738464 under the recessive genetic model was more evident in younger (<65-year-old), male, overweight patients and smokers, as well as in subgroups of Fuhrman III + IV and clinical stage I + II disease (Table 3) . After calculating FPRP values, we found that the association was still noteworthy for all subgroups except for the ever-smokers and those with Fuhrman grade III + IV, when the assumption of prior probability was 0.1 (Supplementary Table S1 , available at Carcinogenesis Online).
Allelic variants of rs2738464 affect miR-330 regulation of the LDLR 3′-untranslated region
The mRNA secondary structure is an important factor affecting the highly complicated interactions between mRNA and miRNA (23) . We, therefore, evaluated the effect of the LDLR 3′-UTR SNP rs2738464 on the local secondary structure of LDLR mRNA, according to the MFE value, using in silico analysis. After inputting a 192 bp fragment of the LDLR 3′-UTR containing rs2738464 and changing the rs2738464 allele from C to G, we found an obvious change in the MFE, from −49.17 kcal/mol to −46.62 kcal/mol (Figure 1) .
According to the in silico results (http://snpinfo.niehs.nih. gov/snpfunc/htm), rs2738464 has the potential to alter the effect of the combination of nine miRNAs on the LDLR 3′-UTR (Supplementary Figure S2 , available at Carcinogenesis Online). However, because miR-1201 could not be found in miRBase, we analysed the remaining eight miRNAs. We detected baseline levels of these eight miRNAs in the three human RCC cell lines, HeLa cells and HK-2 cells (Supplementary Figure S3 , available at Carcinogenesis Online). To explore whether allelic variants of rs2738464 could affect miRNA regulation of the LDLR 3′-UTR, we co-transfected miR-330 mimics and psiCHECK2:control, psiCHECK2:rs2738464C or psiCHECK2:rs2738464G plasmid DNA into five cell lines. We found that the relative luciferase activity was significantly decreased in four cancer cell lines transfected with psiCHECK2:rs2738464G compared with those transfected with psiCHECK2:rs2738464C, although this was not seen in HK-2 cells (Figure 1) . No significant differences were observed between groups with respect to the other seven miRNAs (Supplementary Figure S4 , available at Carcinogenesis Online).
Association between LDLR rs2738464 variants and levels of LDLR mRNA and protein
We next detected the levels of LDLR mRNA in 100 adjacent normal kidney tissues and assessed the association between LDLR rs2738464 variants and LDLR mRNA levels. We observed 53 CC, 36 CG and 11 GG carriers of LDLR rs2738464, and the mRNA levels were significantly different among the three groups (ANOVA, P < 0.05). Compared with CC carriers, GG carriers showed significantly increased levels of LDLR mRNA (P < 0.05). No significant differences in LDLR mRNA levels were seen between CC and CG carriers, or between CG and GG carriers (Figure 2) .
We selected a further 188 patients, who differed from the above 100 cases, for subset analysis with respect to the association of rs2738464 variants with LDLR protein levels in adjacent normal kidney tissues (detailed information is listed in Supplementary Table S3 , available at Carcinogenesis Online). There were 102 CC, 70 CG and 16 GG carriers among the 188 subjects. The genotype distribution of rs2738464 in these subjects and LDLR protein expression, as shown by IHC staining, are indicated in Figure 2 . Strongly positive, weakly positive and negative staining were observed in 4.9%, 53.9% and 41.2% of CC carriers; 4.3%, 44.3% and 51.4% of CG carriers and 0%, 37.5% and 62.5% of GG carriers, respectively. There were no significant differences in staining intensities among the three groups carrying different genotypes.
Discussion
The current study revealed a significant association between LDLR rs2738464 variant genotypes and a decreased ccRCC risk. Further genotype-phenotype correlation analyses suggested that this SNP might regulate LDLR mRNA levels, thereby contributing to ccRCC risk. We also found that rs2738464 might function by influencing the affinity of miR-330 binding to the 3′-UTR of LDLR. To our knowledge, this is the first study to investigate the association of LDLR miRNA binding site SNPs with ccRCC risk.
LDLR is a ubiquitously expressed cell membrane glycoprotein involved in the binding and internalisation of circulating cholesterol-containing lipoprotein particles. It is a key receptor for maintaining cholesterol homeostasis and is essential for lipid metabolism (24) . LDLR dysfunction is known to contribute to familial hypercholesterolaemia and early onset coronary heart disease (CHD) (25) . However, to date, relatively few studies have explored the association between LDLR polymorphisms and physiological disorders, and most have focused on cardiovascular diseases.
Several genome-wide association studies reported that LDLR polymorphisms are associated with serum lipid levels (26) (27) (28) . Van Zyl et al. found that a rare SNP in the promoter region of LDLR (rs17249141) was significantly associated with lower LDL levels, while four other SNPs (rs2738447, rs14158, rs2738465 and rs3180023) were significantly associated with increased LDL levels (29) . Another study revealed a significant relationship between LDLR rs688 and primary intracerebral haemorrhage (30) . A recent meta-analysis reported an association between LDLR rs2228671 and a reduced risk of CHD (31), whereas Andreotti et al. observed that patients carrying the T allele of LDLR rs1003723 had a 1.5-fold increased risk of developing bile duct cancer (32) .
In the present study, we observed a significant association between LDLR rs2738464 and a reduced ccRCC risk, with the variant C allele as the risk allele. This provides evidence for a role for LDLR SNPs in the underlying mechanism of ccRCC carcinogenesis. Although rs2738464 has not previously been reported to be associated with cancer risk, it was associated with LDL levels in an earlier study (33) . We did not evaluate the relationship between LDLR polymorphisms and LDL levels in our study; however, we predict that LDLR genetic variants partially contribute to ccRCC susceptibility by affecting lipid profile levels. miRNAs participate in various cellular processes, including carcinogenesis, by specifically binding and cleaving mRNAs or inhibiting their translation (15, 34) . They have also been shown to contribute to RCC development (35) . SNPs located at the binding sites of miRNAs may influence the binding process, so could be involved in cancer development and possibly drug resistance (36, 37) . This has previously been investigated with respect to ovarian cancer and cervical cancer, as well as platinum resistance (38, 39) , but no studies have focused on RCC and SNPs at miRNA binding sites. Our current finding that LDLR rs2738464G is associated with a decreased ccRCC risk is biologically plausible because the G allele associated with ccRCC risk may reflect the altered MFE, as well as changes in gene expression. Additionally, rs2738464 C>G only affected the binding process of miR-330 to the LDLR 3′-UTR. Consequently, the LDLR rs2738464 G allele might function by affecting the affinity of this binding, thus regulating LDLR expression levels.
We observed significantly different LDLR mRNA levels among different genotypes; however, no differences were observed for LDLR protein levels. A number of reasons may explain this inconsistency. First, we measured mRNA and protein levels of LDLR in different subjects, which may have resulted in selection bias; second, the mRNA translation process may be regulated by other factors that could affect protein levels and third, because ccRCC derives from proximal tubular epithelial cells, we were only able to determine LDLR protein localisation by IHC staining around the proximal tubular region, whereas we did not distinguish between this region and the adjacent normal kidney tissue ultrastructure when detecting LDLR mRNA. Although we found no evidence that the rs2738464 genotype affects LDLR protein levels, we cannot exclude the possibility that this SNP might play a combined role in association with other SNPs, because a single SNP may not be sufficient for the overall risk prediction (40) .
It is important to note the limitations of the present study. First, the clinical data were analysed retrospectively, and cases and controls were not recruited during the same period, which introduces selection bias and information bias. However, we tried to minimise the intrinsic bias by frequency-matching cases and controls, and making adjustments for potential confounding factors in the multivariate analyses. Second, some observations may reflect the limited sample sizes of the subgroups. For example, hypertension is a well-known risk factor of RCC (4), but we did not determine the hypertension history of all subjects. Third, we observed that LDLR rs2738464 C>G affected the binding process of miR-330 to the LDLR 3′-UTR, yet miR-330 expression was relatively lower in all RCC cell lines in our study; thus, we did not elucidate the role of miR-330 in RCC development. In addition, although mRNA levels were determined in triplicate and the mean value was used, mRNA levels might have fluctuated because of mRNA instability. Further studies are therefore necessary to validate our findings in a large-scale population and to determine the mechanisms by which LDLR variants influence the expression of LDLR, and subsequently contribute to ccRCC carcinogenesis.
In summary, the present case-control study indicates that the LDLR rs2738464 SNP is associated with a decreased ccRCC risk in the Eastern Chinese Han population. This SNP may function by influencing the affinity of miR-330 binding to the LDLR 3′-UTR, as well as regulating LDLR mRNA expression, suggesting an important role for LDLR variants in ccRCC carcinogenesis. Additional prospective, larger studies are warranted to validate our findings.
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